Common Stock, par value $0.00001 per share
- Symbol
- CLRB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 2.02, 9.01 · 8-K
Cellectar Biosciences, Inc.
CLRBNASDAQEQUITYCurrent
Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On May 14, 2026, we issued a press release announcing our financial results for the quarter ended March 31, 2026, and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Company context
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.
Current securities
Recent company filings
- Results of Operations and Financial ConditionNov 10, 2026
- 10-Q filingNov 10, 2026
- SCHEDULE 13G - filed by Caligan Partners LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by STEMPOINT CAPITAL LP regarding Cellectar Biosciences, Inc.Aug 14, 2026
- SCHEDULE 13G - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Cellectar Biosciences, Inc.Aug 14, 2026
Registered securities in this filing
Cellectar Biosciences, Inc. · 8-K · Filed 2026-05-14
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02. Results of Operations and Financial Condition.
On May 14, 2026, we issued
a press release announcing our financial results for the quarter ended March 31, 2026, and provided a corporate update. A copy of
the press release is furnished as Exhibit 99.1 and is incorporated by reference herein.
Filed exhibits (1)
EX-99.1 2 tm2614602d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Announced Positive 12-month Follow-on Data for Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) Completed Financing of up to $140 Million to Support Initiation of Confirmatory Study of Iopofosine I 131 in r/r WM and Subsequent U.S. FDA Filing for Accelerated Approval Efficacy Results from r/r WM Patients in CLOVER-WaM Phase 2b Study Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy Selected for Presentation at ASCO 2026 Dosed First Patients in Phase 1b Dose Finding Study for CLR 125 in Triple Negative Breast Cancer with Early Dosimetry, Safety and Efficacy Data Expected Mid-year 2026 Company to Hold Webcast and Conference Call at 8:30 AM ET Today FLORHAM PARK, N.J., May 14, 2026 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced financial results for the quarter ended March 31, 2026, and provided a corporate up…
Open exhibit ↗